+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Anti-Retroviral Drugs Market by Drug Class:, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015172
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-Retroviral Drugs Market grew from USD 27.82 billion in 2023 to USD 29.05 billion in 2024. It is expected to continue growing at a CAGR of 4.59%, reaching USD 38.12 billion by 2030.

Anti-retroviral drugs are pivotal in managing HIV/AIDS, primarily inhibiting the virus's replication to prolong the life of patients and improve quality of life. The necessity of these drugs arises from the continuous global burden of HIV, with applications primarily in healthcare settings, clinics, and hospitals, where timely intervention is crucial. The end-use scope extends across various demographics, including infected patients and at-risk populations, emphasizing the importance of adherence to therapeutic regimens. Market insights reveal substantial growth factors including increasing prevalence of HIV, advancements in drug formulations, and supportive government initiatives bolstering research and development. Moreover, the rise of generic drugs and integration of technology in healthcare, such as telemedicine, present potential opportunities for market players. Companies should focus on expanding their reach in underserved regions and investing in research for less toxic and more convenient drug formulations like long-acting injectables. Nonetheless, limitations include the emergence of drug resistance, side effects of existing therapies, and socio-economic barriers hindering access to treatment. Challenges such as stringent regulatory frameworks and significant R&D expenditure also impede market progression. Innovation in this field should be directed towards discovering novel therapeutic classes, improving drug delivery systems, and personalized medicine approaches to enhance efficacy and patient compliance. The market is dynamic, with a shift towards holistic care encompassing both treatment and preventive measures, thus urging stakeholders to explore partnerships for resource optimization. Expanding awareness campaigns and enhancing the affordability and accessibility of drugs in low-income zones can also leverage growth. Overall, strategic foresight and investment in breakthrough technologies, combined with collaborative efforts at both local and international levels, are instrumental in overcoming market challenges and tapping into emerging opportunities.

Understanding Market Dynamics in the Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Introduction of generic antiretroviral drugs leading to cost-effective treatment options
    • Expanding healthcare infrastructure and accessibility in emerging economies
    • Integration of digital health technologies for better patient management and adherence
  • Market Restraints
    • Stigma and social barriers limiting the uptake of anti-retroviral therapies
  • Market Opportunities
    • Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
    • Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
    • Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
  • Market Challenges
    • Stringent regulatory compliance and complex approval procedures

Exploring Porter’s Five Forces for the Anti-Retroviral Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Retroviral Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Retroviral Drugs Market

External macro-environmental factors deeply influence the performance of the Anti-Retroviral Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Retroviral Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories Ltd., APOTEX INC., Aurobindo Pharma Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Hetero Drugs Limited, Janssen Pharmaceuticals, Inc. by Johnson & Johnson, Jubilant Life Sciences Limited, Lupin Limited, MacroGenics, Inc., Merck & Co., Inc., Mylan Laboratories by Viatris Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Anti-Retroviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class:
    • Entry Inhibitors
    • Fixed-dose Combinations
    • Integrase Inhibitors
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Nucleoside Reverse Transcriptase Inhibitors
    • Protease Inhibitors
  • Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Application
    • HIV Treatment
    • Post-exposure Prophylaxis
    • Pre-exposure Prophylaxis
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Introduction of generic antiretroviral drugs leading to cost-effective treatment options
5.1.1.2. Expanding healthcare infrastructure and accessibility in emerging economies
5.1.1.3. Integration of digital health technologies for better patient management and adherence
5.1.2. Restraints
5.1.2.1. Stigma and social barriers limiting the uptake of anti-retroviral therapies
5.1.3. Opportunities
5.1.3.1. Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
5.1.3.2. Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
5.1.3.3. Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
5.1.4. Challenges
5.1.4.1. Stringent regulatory compliance and complex approval procedures
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-Retroviral Drugs Market, by Drug Class:
6.1. Introduction
6.2. Entry Inhibitors
6.3. Fixed-dose Combinations
6.4. Integrase Inhibitors
6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
6.6. Nucleoside Reverse Transcriptase Inhibitors
6.7. Protease Inhibitors
7. Anti-Retroviral Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intravenous
7.3. Oral
7.4. Subcutaneous
8. Anti-Retroviral Drugs Market, by Application
8.1. Introduction
8.2. HIV Treatment
8.3. Post-exposure Prophylaxis
8.4. Pre-exposure Prophylaxis
9. Anti-Retroviral Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Anti-Retroviral Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Anti-Retroviral Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Anti-Retroviral Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. FDA approval of Dovato for adolescents 12 and older living with HIV marks a significant breakthrough in treatment and adherence
13.3.2. Zydus Lifesciences secures USFDA nod for generic Darunavir Tablets
13.4. Strategy Analysis & Recommendation
13.4.1. Cipla Limited
List of Figures
FIGURE 1. ANTI-RETROVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-RETROVIRAL DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-RETROVIRAL DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 40. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 62. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 66. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 74. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 98. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 115. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 119. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 123. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 147. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 151. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 155. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 183. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 195. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anti-Retroviral Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • APOTEX INC.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Janssen Pharmaceuticals, Inc. by Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Lupin Limited
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mylan Laboratories by Viatris Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • ViiV Healthcare

Methodology

Loading
LOADING...

Table Information